Pharmacist Outreach Can Help Reduce Hypoglycemia Risk | ADA 2025
Drug Topics
JUNE 24, 2025
Data presented at ADA 2025 showed patients who received outreach from a clinical pharmacist were more likely to be prescribed safer diabetes regimens.
Drug Topics
JUNE 24, 2025
Data presented at ADA 2025 showed patients who received outreach from a clinical pharmacist were more likely to be prescribed safer diabetes regimens.
Drug Topics
MARCH 15, 2025
Among the drugs presented, Biktarvy and lenacapavir, teropavimab, and zinlirvimab (LTZ) demonstrate rates of suppression of HIV, and vesatolimod is well tolerated.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
JULY 1, 2025
Jon Easter, RPh, discusses pharmacists’ ability to improve patient engagement in diabetes care following his presentation at the American Diabetes Association’s 85th Scientific Sessions.
Drug Topics
JUNE 23, 2025
Data presented at ADA’s 85th Scientific Sessions showed patients who received physician education with clinical pharmacist outreach had significantly better A1c levels at 6 months compared to usual care.
Drug Topics
JULY 1, 2025
In an abstract presented at the American Diabetes Association 85th Scientific Sessions, researchers tested the effectiveness of an AI-driven program for improving glycemic control.
Drug Topics
JULY 2, 2025
In a recap of his presentation at the American Diabetes Association’s 85th Scientific Sessions, Jon Easter, RPh, discussed the role of pharmacists in team-based diabetes care.
Pharmafile
JUNE 10, 2025
The data was presented at the European Renal Association Congress on 6 June 2025 […] The post Takeda presents positive results from trial of chronic kidney disease treatment appeared first on Pharmafile. The Japanese biopharma is now looking ahead to a prospective phase 3 trial of mezagitamab.
Let's personalize your content